Polymorphic variant rs1739843 of heat shock protein beta-7 (HSPB7) gene and its relationship with on clinical profile and outcomes in patients with hypertrophic cardiomyopathy (results of a 10-year follow-up)

Aim. To determine the impact of polymorphic variant rs1739843 of the HSPB7 gene on clinical profile and outcomes in patients with hypertrophic cardiomyopathy (HCM).

Material and methods. The study population consisted of 108 patients with HCM ≥45 years old. The control group included 192 healthy donors. The design of the study included an assessment of the clinical course, determining the outcome of HCM using a new methodological approach proposed by Rowin EJ, et al. (2017). Polymorphic variant rs1739843 of the HSPB7 gene was genotyped by allele-specific real-time polymerase chain reaction (PCR) assay.

Results. It was found a significant increase in frequency of TT genotype of rs1739843 of the HSPB7 gene in patients with HCM — 20,4%, compared with control group — 4,2% (ТТ: ТС+СС, odds ratio (OR) =5,88, 95% confidence interval (CI) =2,52-13,75, p<0,001). High prevalence of CC genotype of rs1739843 of the HSPB7 gene was observed in control group — 80,2% vs 31,5% in HCM group (CC: ТС+TT, OR=0,11, 95% CI=0,07-0,19, p<0,001). The allele frequency (С:Т) also differs between HCM and control groups — 55,6:44,4% in HCM vs 88,02:11,98% in control group (OR=5,88, 95% CI=3,91-8,85, p<0,001). It was also found a significant increase in frequency of TT genotype and T allele of rs1739843 of the HSPB7 gene in HCM patients with oligosymptomatic HCM course — 16,7%, compared with control group — 4,2% (ТТ: ТС+СС, OR=4,60, 95% CI=1,63-12,99, p<0,001). HCM patients ≥45 years old showed a significant increase in T allele frequency in cases of presence of 2 (FC III-IV CHF (chronic heart failure)+AF (atrial fibrillation), 18,8% vs 6,6%) and 3 adverse pathways (FC III-IV CHF+AF+SCD (sudden cardiac death), 4,2% vs 1,6%).

Conclusion. HCM progression along 2 and more adverse pathways in patients ≥45 years old has been characterized with adverse outcome. The T allele and TT genotype of rs1739843 of the HSPB7 gene were more frequent in patients with HCM ≥45 years old, compared with control group. It was also found a significant increase in frequency of TT genotype and T allele of rs1739843 of the HSPB7 gene in HCM patients with oligosymptomatic HCM course, compared with control group.

Allele T of rs1739843 of the HSPB7 gene is associated with 2 and more adverse pathways of HCM progression.

1. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.

2. Brundel BJ, Henning RH, Ke L, et al. Heat shock protein upregulation protects against pacinginduced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. Journal of Molecular and Cellular Cardiology. 2006;41(3):555-62. doi:10.1016/j.yjmcc.2006.06.068.

3. Ke L, Qi XY, Dijkhuis AJ, et al. Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. Journal of Molecular and Cellular Cardiology. 2008;45(5):685-93. doi:10.1016/j.yjmcc.2008.08.012.

4. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. Journal of Biological Chemistry. 2005;280(39):33097-100. doi:10.1074/jbc.R500010200.

5. Rudebusch J, Benkner A, Poesch A, et al. Dynamic adaptation of myocardial proteome during heart failure development. PLoS One. 2017;12(10):e0185915. doi:10.1371/journal.pone.0185915.

6. Golenhofen N, Perng MD, Quinlan RA, et al. Comparison of the small heat shock proteins alphaB-crystallin, MKBP, HSP25, HSP20, and cvHSP in heart and skeletal muscle. Histochemistry and Cell Biology. 2004;122(5):415-25. doi:101007/s00418-004-0711-z.

7. Rowin EJ, Maron MS, Chan RH, et al. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 2017;120(12):2256-64. doi:10.1016/j.amjcard.2017.08.048.

8. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Journal of The American College of Cardiology. 2015;65(18):1915-28. doi:10.1016/j.jacc.2015.02.061.

9. Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >60 years of age. Circulation. 2013;127(5):585-93. doi:10.1161/CIRCULATIONAHA.112.136085.

10. Poliakova AA, Semernin EN, Streltcova AA, et al. Hypertrophic cardiomyopathy in elderly people. Arterialnaya Gipertenziya. 2013;19(6):502-5. (In Russ.) doi:10.18705/1607-419X-2013-19-6-502-505.

11. Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-98. doi:10.1161/CIRCULATIONAHA.117.033200.

12. Cappola TP, Li M, He J, et al. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. Circulation: Cardiovascular Genetics. 2010;3(2): 147-54. doi:10.1161/CIRCGENETICS.109.898395.

13. Tishkova VM, Prokopova VV, Kostareva AA, et al. Prevalence of rs10519210, rs1739843, and rs6787362 polymorphisms in patients with CHF of ischemic origin. Russian Heart Failure Journal. 2017; 18(2): 115-21. (In Russ.) doi:10.18087/rhfj.2017.2.2318.

14. Barlassina C, Dal FC, Lanzani C, Manunta P, et al. Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt- sensitive hypertension. Human Molecular Genetics. 2007;16(13):1630-8. doi:10.1093/hmg/ddm112.

15. Sile S, Velez DR, Gillani NB, et al. Haplotype diversity in four genes (CLCNKA, CLCNKB, BSND, NEDD4L) involved in renal salt reabsorption. Human Heredity. 2008;65(1):33-46. doi:10.1159/000106060.